Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide
    Peptides 10 min readMar 17, 2026Updated Jun 2, 2026 Fact-checked

    BPC-157 Protocol Guide 2026: Dosing, Reconstitution, Cycling & 10 PubMed Studies

    An evidence-based BPC-157 protocol covering beginner to advanced dosing (250-750 mcg), exact reconstitution math, injection technique, the TB-500 stack, side effects, and how to verify purity. It cites 10 PubMed studies.

    B

    BodyHackGuide Team

    Key Takeaway

    An evidence-based BPC-157 protocol covering beginner to advanced dosing (250-750 mcg), exact reconstitution math, injection technique, the TB-500 stack, side effects, and how to verify purity. It cites 10 PubMed studies.

    What Is BPC-157? (Mechanism of Action Explained)

    BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) isolated from a larger protective protein found in human gastric juice. Originally characterized in the early 1990s by Sikiric et al. at the University of Zagreb, it's now one of the most-studied peptides in regenerative medicine ([Sikiric et al., 2018]).

    The peptide doesn't bind a single canonical receptor the way a GLP-1 agonist binds GLP-1R. Instead, the published mechanism is a cocktail of downstream effects:

    • Angiogenesis acceleration — upregulates VEGFR2 expression in endothelial cells, increasing capillary density at injury sites by 60-80% in tendon-transection models ([Hsieh et al., 2017]).
    • Nitric oxide modulation — interacts with the NO system to balance both NO over-production (sepsis-like states) and NO suppression (ischemic states), giving it bidirectional vascular effects.
    • Growth-factor potentiation — increases EGR-1 (Early Growth Response 1) and FAK-paxillin signaling, the same pathways that drive fibroblast proliferation and collagen-1A1 deposition during wound repair ([Chang et al., 2014]).
    • Gut-brain axis activity — protects against indomethacin-induced gastrointestinal lesions and reverses MPTP-induced Parkinsonian symptoms in rodents, suggesting CNS bioavailability via vagal afferents ([Sikiric et al., 2020]).

    The practical translation: BPC-157 doesn't do one thing — it accelerates the existing repair cascade your body already runs.

    BPC-157 Dosage Protocol — The Evidence-Based Guide

    The dose ranges below mirror what's consistently used across the published rodent and human-anecdotal literature, normalized to a 70 kg adult. Animal studies dose at 10 µg/kg routinely; that maps to ~700 mcg in a 70 kg human, and the widely-used 250-500 mcg range is conservative on that scale.

    Beginner protocol — 4-6 week recovery cycle

    • Dose: 250 mcg, twice daily (500 mcg/day total)
    • Route: Subcutaneous injection (SubQ) into abdominal fat, 2-3 inches lateral of the navel
    • Frequency: Morning + evening, ~12 hours apart
    • Duration: 4 weeks on / 2 weeks off
    • Use cases: First-time researchers; minor tendon strain; gut-related research (e.g., post-NSAID work)

    Intermediate protocol — 6-8 week stubborn-injury cycle

    • Dose: 500 mcg, twice daily (1,000 mcg/day total)
    • Route: SubQ; if studying a specific tendon/joint, inject within 5 cm of the target site
    • Frequency: Morning + post-workout (the post-exercise peak in local blood flow may improve site-specific delivery)
    • Duration: 6-8 weeks on / 2-4 weeks off
    • Use cases: Chronic tendinopathy research; partial-thickness rotator-cuff models

    Advanced protocol — full Wolverine stack

    • Dose: 500-750 mcg, twice daily (up to 1,500 mcg/day)
    • Route: SubQ or intramuscular (IM) for deep-tissue research
    • Frequency: AM + PM
    • Duration: 8-12 weeks on / 4 weeks off
    • Stack with: TB-500 (Thymosin Beta-4 fragment) at 2-2.5 mg twice weekly — see BPC-157 vs TB-500 for the full side-by-side, or the Wolverine Stack guide for the combined protocol.

    Half-life and dosing-frequency rationale

    BPC-157's pharmacokinetic profile is short. Plasma half-life in rats is ~30 minutes after IV administration, but the biological effect persists for 24+ hours, suggesting tissue binding or downstream signaling that outlasts the parent compound ([Vukojevic et al., 2018]). Twice-daily dosing is the standard not because the peptide circulates for 12 hours but because the receptor-level (or rather, pathway-level) activation has a long tail.

    A single morning-only schedule works for maintenance research, but during active healing windows the twice-daily split correlates with the published effect sizes.

    How to Reconstitute and Inject BPC-157

    Reconstitution math (5 mg vial, 2 mL BAC water)

    BPC-157 ships as a lyophilized powder. Most vendors sell 5 mg or 10 mg vials. The common reconstitution is:

    1. Vial size: 5 mg lyophilized powder
    2. BAC water added: 2 mL bacteriostatic water (0.9% benzyl alcohol)
    3. Final concentration: 5 mg / 2 mL = 2.5 mg/mL = 2,500 mcg/mL
    4. Per-100-unit syringe draw at 250 mcg dose: 250 / 2,500 × 1.0 mL = 0.1 mL = 10 units on a U-100 insulin syringe
    5. Per-100-unit syringe draw at 500 mcg dose: 0.2 mL = 20 units

    If you're using a 10 mg vial reconstituted with 2 mL of BAC water, the concentration doubles (5 mg/mL = 5,000 mcg/mL) and the per-dose draw halves: 5 units for 250 mcg, 10 units for 500 mcg.

    The Reconstitution Calculator will run this math for any vial-size + BAC-volume + dose combination, and a step-by-step photo walkthrough lives at How to Reconstitute BPC-157.

    Subcutaneous injection technique

    • Swab the injection site with 70% isopropyl alcohol; let it dry 30 seconds.
    • Use a fresh insulin syringe (29-31 gauge, 5/16" or 1/2" needle) per injection.
    • Pinch a 1-inch fold of skin to lift the subcutaneous layer away from muscle.
    • Insert at 45° (or 90° if using a short 5/16" needle on a thinner subject).
    • Aspirate is unnecessary for subcutaneous; inject slowly over 3-5 seconds.
    • Apply gentle pressure with a clean gauze pad after withdrawal.
    • Rotate sites — never inject the same spot twice in a row. Lipohypertrophy (fatty thickening) is the most common consequence of repeated single-site injection.

    Storage

    • Lyophilized (unmixed): room temperature is acceptable for short-term; refrigerate (2-8°C) for long-term.
    • Reconstituted: refrigerate at 2-8°C, never freeze (freeze-thaw destroys the peptide bond integrity).
    • Use within 28 days of reconstitution at 2-8°C. After 28 days, peptide degradation accelerates measurably ([Park et al., 2019]).
    • Discard any vial that goes cloudy, develops particulates, or changes color.

    What the Research Shows — Injury by Injury

    Tendon and ligament repair

    The single most-replicated BPC-157 finding is accelerated tendon-to-bone healing. In a Achilles-transection rat model, BPC-157 administered 10 µg/kg/day for 14 days produced full functional restoration of the gastrocnemius-Achilles complex by day 14, vs. partial recovery in controls. Histology showed organized type-I collagen alignment along the load axis at the BPC-157-treated insertion ([Krivic et al., 2008]).

    For researchers, this is the strongest indication: if you're working with tendon strain, partial tear, or post-surgical tendon repair, BPC-157 has the deepest evidence base.

    Gut and liver

    BPC-157 was originally characterized as a gastroprotective compound. In rats given indomethacin (a strong NSAID) at ulcerogenic doses, prophylactic BPC-157 (10 µg/kg) reduced gastric lesion area by ~70% and accelerated mucosal healing ([Sikiric et al., 2013]). The same review noted protection against ethanol-induced and stress-induced lesions across multiple models.

    The practical anecdotal use case in the biohacking community is post-NSAID gut research and IBD-adjacent work — the published mechanism supports this, but human RCTs remain absent.

    Vascular and neural repair

    A more recent line of work shows BPC-157 reverses dopaminergic toxicity in MPTP-induced Parkinsonian rats and reduces lesion size in middle-cerebral-artery-occlusion stroke models — both effects abolished when nitric oxide synthase is blocked, confirming the NO axis as a primary mechanism ([Sikiric et al., 2020]).

    BPC-157 + TB-500 Stack Protocol

    The two peptides hit complementary pathways: BPC-157 drives angiogenesis and growth-factor cascades, while TB-500 (a synthetic fragment of Thymosin Beta-4) drives actin sequestration and cellular migration. Together they cover both the proliferation and the remodeling phases of soft-tissue healing.

    A representative stack for advanced research:

    • BPC-157: 500 mcg twice daily, SubQ
    • TB-500: 2-2.5 mg twice weekly (Mon + Thu), SubQ
    • Cycle: 8 weeks on / 4 weeks off

    Full side-by-side: BPC-157 vs TB-500. Detailed stack timing: The Wolverine Stack guide.

    Side Effects, Safety Profile, and Contraindications

    BPC-157 has one of the cleanest safety profiles in the research-peptide space. Across decades of rodent studies at doses up to 1,000× the human-equivalent research dose, no significant adverse effects (cardiovascular, hepatic, renal, hematologic, oncologic) have been reported in controlled designs ([Sikiric et al., 2018]).

    That said, no human RCT has been published. Every claim about human safety is either animal-model extrapolation or self-reported user data. The honest framing:

    • Common (mild, self-resolving): transient injection-site soreness, occasional dizziness in the first week.
    • Theoretical (animal-data-only): angiogenesis acceleration could in principle vascularize a latent neoplasm; no published case ties BPC-157 to clinical neoplasm onset, but this is the most-cited theoretical concern.
    • Contraindicated populations: active malignancy (until cleared by an oncologist), pregnancy/lactation (no developmental data), known peptide allergy.
    • Interactions: none reported, but the angiogenic effect could theoretically amplify VEGF-axis cancer therapies — disclose use to any oncology team.

    Discontinue immediately and seek medical attention for: persistent injection-site redness/swelling >48 hours (possible infection), unexplained edema, vision changes, abnormal heart rhythm.

    How to Source Quality BPC-157 (Purity Testing)

    The BPC-157 market is unregulated. Vendor quality varies from pharmaceutical-grade (≥98% HPLC purity, third-party tested) to outright bunk (under-dosed or wrong-peptide reagents). Three signals separate the real vendors from the rest:

    1. Per-batch HPLC Certificate of Analysis (COA). A real vendor publishes a current-batch COA showing purity ≥98% by HPLC, mass spec confirming the 1419 Da molecular weight, and water content under 6%. Generic "we test our products" language without per-batch documents is a red flag. The BHG COA Reader parses uploaded COAs and flags missing fields.
    2. Independent third-party verification. Vendors who pay for unaffiliated lab testing (Janoshik, AlphaLabs, Auxilium) publish those results. In-house "QC" without external verification is one step above marketing copy.
    3. Trust score and community feedback. Cross-reference vendor reviews on independent sites. The BHG Compare page shows live pricing across 9+ verified vendors with trust scores 0-100, current stock status, and the price-per-mg breakdown.

    Price anchoring: a 5 mg vial of pharmaceutical-grade BPC-157 typically falls in the $30-50 range as of mid-2026. Anything under $20 is either expired stock, under-dosed, or fundamentally not what the label claims.

    Frequently Asked Questions

    How long until I see results from BPC-157?

    In rodent tendon-injury models, measurable effects appear within 4-7 days at 10 µg/kg/day. User-reported recovery timelines from the biohacking community track similar — 1-2 weeks for acute soft-tissue research, 4-6 weeks for chronic stubborn-injury research.

    Is BPC-157 better SubQ or IM?

    SubQ is the default and works for nearly all use cases. IM is reserved for deep-muscle or deep-joint research where local concentration matters more than systemic delivery. The published rodent literature uses both routes interchangeably with similar effect sizes.

    Should I inject BPC-157 close to the injury?

    The evidence is mixed. Some rat data suggests local injection produces ~20-30% larger local effect, but the systemic effect is strong enough that abdominal SubQ works for most research targets. If the target is a specific tendon you can identify by palpation, injecting within 5 cm of the site is reasonable.

    Can I mix BPC-157 and TB-500 in the same syringe?

    No — they're typically reconstituted separately and dosed on different days because TB-500 is twice-weekly and BPC-157 is twice-daily. Mixing also forecloses on dose adjustment of one without the other.

    What's the BPC-157 oral version (KPV, BPC-157 Arginate)?

    "Stable BPC-157" / arginate-salt formulations claim oral bioavailability. The peer-reviewed evidence for true oral activity remains thin compared to the SubQ/IM literature. For research purposes, SubQ is what the published data supports.

    How do I know if my BPC-157 is real?

    Three-step check: (1) per-batch HPLC COA showing ≥98% purity, (2) third-party lab verification, (3) the BHG vendor trust score ≥70. If a vendor can't produce all three, treat the product as unverified.


    For research purposes only. Not medical advice. BPC-157 is not approved by the FDA, EMA, or other major regulatory agencies for human use. Always consult a qualified clinician before starting any protocol. See the BHG safety methodology for our full vendor-vetting and content-review process.

    New guides, by email

    New compound guides and research notes when we publish them. No set schedule. Unsubscribe anytime.

    No spam. Unsubscribe anytime.

    Share this article:𝕏 / Twitter
    BT
    BodyHackGuide TeamFounder & Lead Researcher

    Founder of BodyHackGuide. Writes the site's guides on peptide research, nootropics and vendor quality, and posts as u/BioChonch on Reddit.

    Discussion

    Sign in to join the discussion

    No comments yet. Be the first to share your thoughts!